Back to results
US 8,263,072 B2Granted
ADAMTS4 as a blood biomarker and therapeutic target for chronic renal failure
AssigneeGenera Istrazivanja d.o.o.
InventorsLovorka Grgurevic, Slobodan Vukicevic
Life of this patent
Estimating the term…
Abstract
ADAMTS4 is found to be useful as a blood biomarker for chronic renal failure and also as a therapeutic target for treating chronic renal failure in a human individual. A change in the level of expression of selected genes as disclosed herein in kidney tissue of an individual may also be used to diagnose chronic renal failure in an individual.
Claims4
A method of treating chronic renal failure in a human individual in need of treatment thereof comprising the step of:
- administering to the individual an antibody to human ADAMTS4;
- wherein said antibody is administered in an amount effective to reduce the level of ADAMTS4 in the blood.
Dependencies are inferred from the claim text.